The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men.
Open accessAbstract
OBJECTIVE: To examine the association between the serum lipoprotein (a) concentration and subsequent coronary heart disease. DESIGN: Prospective case-control study based on a six year follow up of a general population sample of men aged 50 at baseline in 1983-4. Serum samples were frozen at the time of the baseline examination and kept at -70 degrees C for six years, after which the lipoprotein (a) concentrations in the samples were measured in cases and controls. SETTING: City of Gothenburg, Sweden. SUBJECTS: 26 Men, from a general population sample of 776 men, who had sustained a myocardial infarction or died of coronary heart disease during the six years and 109 randomly selected controls from the same sample who had remained free of myocardial infarction. In neither cases nor controls was there a history of myocardial infarction at baseline. MAIN OUTCOME MEASURES: Proportion of myocardial infarction or deaths from coronary heart disease, or both, in relation to the serum lipoprotein (a) concentration. RESULTS: Men who suffered coronary heart disease had significantly higher serum lipoprotein (a) concentrations than controls (mean difference 105 mg/l; 95% confidence interval 18 to 192 mg/l). Men with the highest fifth of serum lipoprotein (a) concentrations (cut off point 365 mg/l) suffered a coronary heart disease rate which was more than twice that of men with the lowest four fifths of concentrations. Logistic regression analysis showed the serum lipoprotein (a) concentration to be significantly associated with coronary heart disease independently of other risk factors. CONCLUSION: The serum lipoprotein (a) concentration in middle aged men is an independent risk factor for subsequent myocardial infarction or death from coronary heart disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens
Clauss, A. (1957) · Acta Haematologica · doi:10.1159/000205234 · Cited by 3,208
cDNA sequence of human apolipoprotein(a) is homologous to plasminogen
McLean, J. W., Tomlinson, J. E., Kuang, W.-J., Eaton, D. L., Chen, E. Y., Fless, G. M., Scanu, A. M., & Lawn, R. M. (1987) · Nature · doi:10.1038/330132a0 · Cited by 1,886
PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION
Hamsten, A., Walldius, G., Szamosi, A., Blombäck, M., Faire, U., Dahlén, G., Landou, C., & Wiman, B. (1987) · The Lancet · doi:10.1016/s0140-6736(87)93050-9 · Cited by 1,474
The mysteries of lipoprotein(a).
Utermann, G. (1989) · Science · doi:10.1126/science.2530631 · Cited by 1,257
Dahlen, G. H., Guyton, J. R., Attar, M., Farmer, J. A., Kautz, J. A., & Gotto, A. M. (1986) · Circulation · doi:10.1161/01.cir.74.4.758 · Cited by 911
Utermann, G., Menzel, H. J., Kraft, H. G., Duba, H. C., Kemmler, H. G., & Seitz, C. (1987) · Journal of Clinical Investigation · doi:10.1172/jci113093 · Cited by 881
Lp(a) Lipoprotein as a Risk Factor for Myocardial Infarction
Rhoads, G. G. (1986) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1986.03380180102027 · Cited by 783
Armstrong, V. W., Cremer, P., Eberle, E., Manke, A., Schulze, F., Wieland, H., Kreuzer, H., & Seidel, D. (1986) · Atherosclerosis · doi:10.1016/0021-9150(86)90099-7 · Cited by 626
Seed, M., Hoppichler, F., Reaveley, D., McCarthy, S., Thompson, G. R., Boerwinkle, E., & Utermann, G. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005243222104 · Cited by 585
Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients.
Rath, M., Niendorf, A., Reblin, T., Dietel, M., Krebber, H. J., & Beisiegel, U. (1989) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.9.5.579 · Cited by 446
CARLSON, L. A., HAMSTEN, A., & ASPLUND, A. (1989) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1989.tb01393.x · Cited by 443
Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age
Sandkamp, M., Funke, H., Schulte, H., Köhler, E., & Assmann, G. (1990) · Clinical Chemistry · doi:10.1093/clinchem/36.1.20 · Cited by 417
Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen.
Eaton, D. L., Fless, G. M., Kohr, W. J., McLean, J. W., Xu, Q. T., Miller, C. G., Lawn, R. M., & Scanu, A. M. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3224 · Cited by 416
Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction
MURAI, A., MIYAHARA, T., FUJIMOTO, N., MATSUDA, M., & KAMEYAMA, M. (1986) · Atherosclerosis · doi:10.1016/0021-9150(86)90048-1 · Cited by 383
Transient changes of serum lipoprotein(a) as an acute phase protein
Maeda, S., Abe, A., Seishima, M., Makino, K., Noma, A., & Kawade, M. (1989) · Atherosclerosis · doi:10.1016/0021-9150(89)90218-9 · Cited by 365
Lipoprotein(a) as a strong indicator for cerebrovascular disease.
Zenker, G., Költringer, P., Boné, G., Niederkorn, K., Pfeiffer, K., & Jürgens, G. (1986) · Stroke · doi:10.1161/01.str.17.5.942 · Cited by 329
APOLIPOPROTEINS (a), AI, AND B AND PARENTAL HISTORY IN MEN WITH EARLY ONSET ISCHAEMIC HEART DISEASE
Durrington, P. N., Hunt, L., Ishola, M., Arrol, S., & Bhatnagar, D. (1988) · The Lancet · doi:10.1016/s0140-6736(88)91895-8 · Cited by 283
Lipoprotein Lp(a). A risk factor for myocardial infarction.
Hoefler, G., Harnoncourt, F., Paschke, E., Mirtl, W., Pfeiffer, K. H., & Kostner, G. M. (1988) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.8.4.398 · Cited by 241
Gonzalez-Gronow, M., Edelberg, J. M., & Pizzo, S. V. (1989) · Biochemistry · doi:10.1021/bi00432a005 · Cited by 218
Lipoprotein(a) as a strong indicator for cerebrovascular disease.
GZenker, PKöltringer, GBoné, et al. (1986) · Stroke · Cited by 197
Registration of myocardial infarction in the city of Göteborg, Sweden
Elmfeldt, D., Wilhelmsen, L., Tibblin, G., Vedin, J. A., Wilhelmsson, C.-E., & Bengtsson, C. (1975) · Journal of Chronic Diseases · doi:10.1016/0021-9681(75)90005-3 · Cited by 143
Self-citationBIRGITTASUNDELL, I., Nilsson, T. K., Hallmans, G., Hellsten, G., & Dahlén, G. (1989) · Atherosclerosis · doi:10.1016/0021-9150(89)90062-2 · Cited by 129
Lipoprotein a inhibits streptokinase-mediated activation of human plasminogen
Edelberg, J. M., Gonzalez–Gronow, M., & Pizzo, S. V. (1989) · Biochemistry · doi:10.1021/bi00432a004 · Cited by 117
Masarei, J. R. L., Rouse, I. L., Lynch, W. J., Robertson, K., Vandongen, R., & Beilin, L. J. (1984) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/40.3.468 · Cited by 82
Cited by
The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
Epstein, F. H., Fuster, V., Badimon, L., Badimon, J. J., & Chesebro, J. H. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201303260506 · Cited by 3,725
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
Lipoprotein(a) and Coronary Heart Disease: Meta-Analysis of Prospective Studies
Danesh, J., Collins, R., & Peto, R. (2000) · Circulation · doi:10.1161/01.cir.102.10.1082 · Cited by 938
Nordestgaard, B. G., & Langsted, A. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r071233 · Cited by 575
Jones, T. H., Arver, S., Behre, H. M., Buvat, J., Meuleman, E., Moncada, I., Morales, A. M., Volterrani, M., Yellowlees, A., Howell, J. D., et al. (2011) · Diabetes Care · doi:10.2337/dc10-1233 · Cited by 548
“Lpa is a strong independent risk factor for premature coronary heart disease (22).”
Background
Metadata
- Authors
- Rosengren, A., Wilhelmsen, L., Eriksson, E., Risberg, B., & Wedel, H.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 1990-12-01
- Volume
- 301
- Issue
- 6763
- Pages
- 1248-1251
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2067318301
- Cited by
- 539
- References
- 24
- FWCI
- 36.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.